Three FcRn inhibitors are approved for generalized myasthenia gravis, with a head-to-head trial of efgartigimod and nipocalimab underway. Emerging therapies including telitacicept, gefurulimab, and CAR-T cell therapy (KYV-101) show promise, while Immunovant's batoclimab failed TED trials.
Over 10 companies are developing 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder, including Roche's satralizumab Phase III pediatric trial and multiple anti-CD20 monoclonal antibody candidates.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07619898 |
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure |
NOT_YET_RECRUITING | PHASE2 |
| NCT07616154 |
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease |
RECRUITING | PHASE2 |
| NCT07352566 |
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07168161 |
BDB-001 Phase III Trial in ANCA-Associated Vasculitis |
RECRUITING | PHASE3 |
| NCT07138898 |
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
RECRUITING | PHASE2 |
| NCT03490539 |
Disease-Modifying Treatments for Myasthenia Gravis |
COMPLETED | |
| NCT03414502 |
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response |
RECRUITING | PHASE3 |
